List view / Grid view
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Daiichi Sankyo has enrolled their first patient in the global phase 3 QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients...
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Proposed changes to the way NICE appraises new treatments could see patients benefiting from the most cost effective treatments nearly three months faster...
14 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Zoptrex, a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer...
14 October 2016 | By Niamh Louise Marriott, Digital Content Producer
OncoGenex’ results, analysed from the Phase 3 trial of custirsen in patients whose non-small cell lung cancer (NSCLC) has progressed following initial...
14 October 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients in the treatment of non small-cell lung cancer...
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Results showed that mortality was higher in patients over 70 who were either not tested with Oncotype DX or had a recurrence score result greater than 18...
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Scancell intends to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor...
13 October 2016 | By Tornado Spectral Systems
Full Raman spectroscopy system joins Tornado Spectral Systems’ stand-alone spectrometers...
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Acquired TTP is an acute, ultra-rare, life-threatening blood clotting disorder in which uncontrolled platelet aggregation and microclot formation cause...
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for Neurocrine Biosciences‘ Ingrezzatm (valbenazine) for the treatment of tardive dyskinesia. The application has been given a prescription drug user fee act (PDUFA) target action date of April 11, 2017. A Priority Review…
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib...
12 October 2016 | By Particle Works
Particle Works – the nano- and microstructured material specialist – provides microencapsulation services for drug development applications, including controlled drug release, solubility enhancement or targeted drug delivery...
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA has assigned a prescription drug user fee act (PDUFA) target date of February 17, 2017 to take a decision on daratumumab in this indication...
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
45% of patients receiving the combination of Tafinlar + Mekinist (95% CI, 39.1%-49.8%) compared with 31% of patients who received vemurafenib monotherapy...
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has released draft guidance recommending Apremilast for the treatment of psoriatic arthritis in adults. This appraisal was a rapid review of the NICE technology appraisal guidance published in December 2015. It focused on cost-effectiveness analyses using a patient access scheme agreement, which provides apremilast at…
